Nevada-based Corstasis Therapeutics announced that the FDA has accepted the company’s NDA for RSQ-777 bumetanide nasal spray, a diuretic for the treatment of edema associated with congestive heart failure, kidney disease, and liver disease. The agency assigned a PDUFA target date of September 14, 2025.
Corstasis CEO Benjamin Esque commented, “We are pleased the FDA has accepted our NDA for bumetanide nasal spray. This milestone brings us closer to providing a simple, easy-to-use outpatient therapy for patients with fluid overload. We look forward to working closely with the FDA throughout the review process.”
Chief Medical Office Brian Kolski said, “Our aim is to reduce the burden on both patients and the healthcare system by offering treatment options outside the hospital setting—potentially lowering costs and improving quality of life.”
Read the Corstasis Therapeutics press release
